{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:54:45Z","timestamp":1767707685554,"version":"3.41.2"},"reference-count":321,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009997","name":"International Headache Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pharmthera.2025.108846","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:55:53Z","timestamp":1744199753000},"page":"108846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics"],"prefix":"10.1016","volume":"270","author":[{"given":"Zoe","family":"Tasma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Garelja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqfan","family":"Jamaluddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyla I.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayla A.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0005","first-page":"29","article-title":"The physiological roles of secretin and its receptor","volume":"1","author":"Afroze","year":"2013","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0010","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/MS9.0000000000001620","article-title":"Novel FDA-approved zavegepant drug for treating migraine","volume":"86","author":"Ahmed","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"S2","key":"10.1016\/j.pharmthera.2025.108846_bb0015","first-page":"S23","article-title":"The concise guide to PHARMACOLOGY 2023\/24: G protein-coupled receptors","volume":"180 Suppl 2","author":"Alexander","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obesity Reviews"},{"issue":"4718","key":"10.1016\/j.pharmthera.2025.108846_bb0025","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.2994212","article-title":"Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide","volume":"229","author":"Amara","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170683","article-title":"Peptides in the regulation of glucagon secretion","volume":"148","author":"Andersen","year":"2022","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0035","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0050","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa2314577","article-title":"A monoclonal antibody to PACAP for migraine prevention","volume":"391","author":"Ashina","year":"2024","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0055","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74101","article-title":"Effector membrane translocation biosensors reveal G protein and betaarrestin coupling profiles of 100 therapeutically relevant GPCRs","volume":"11","author":"Avet","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116235","article-title":"Variable CGRP family peptide signaling durations and the structural determinants thereof","volume":"224","author":"Babin","year":"2024","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104785","article-title":"Adrenomedullin 2\/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin(2) G protein-coupled receptor","volume":"299","author":"Babin","year":"2023","journal-title":"The Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0070","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2011.01717.x","article-title":"Pharmacological characterization of rat amylin receptors: Implications for the identification of amylin receptor subtypes","volume":"166","author":"Bailey","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCRESAHA.123.321673","article-title":"Clinical potential of Adrenomedullin signaling in the cardiovascular system","volume":"132","author":"Balint","year":"2023","journal-title":"Circulation Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0085","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","article-title":"Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain","volume":"22","author":"Benschop","year":"2014","journal-title":"Osteoarthritis and Cartilage"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0090","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/0333102420983282","article-title":"Migraine therapeutics differentially modulate the CGRP pathway","volume":"41","author":"Bhakta","year":"2021","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/mp.2009.141","article-title":"The CRF system, stress, depression and anxiety-insights from human genetic studies","volume":"15","author":"Binder","year":"2010","journal-title":"Molecular Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.yhbeh.2013.04.001","article-title":"Conditioned fear is modulated by CRF mechanisms in the periaqueductal gray columns","volume":"63","author":"Borelli","year":"2013","journal-title":"Hormones and Behavior"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acsptsci.8b00002","article-title":"Molecular signature for receptor engagement in the metabolic peptide hormone amylin","volume":"1","author":"Bower","year":"2018","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0115","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0120","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nature Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0125","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S2213-2600(23)00147-9","article-title":"Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): A randomised, placebo-controlled trial","volume":"11","author":"Brown","year":"2023","journal-title":"The Lancet Respiratory Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0130","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/j.2040-4603.2018.tb00039.x","article-title":"Glucagon-like Peptide-2 and the regulation of intestinal growth and function","volume":"8","author":"Brubaker","year":"2018","journal-title":"Comprehensive Physiology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb0135","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/bip.360370204","article-title":"Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues","volume":"37","author":"Campbell","year":"1995","journal-title":"Biopolymers"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41589-023-01393-4","article-title":"Structural insight into selectivity of amylin and calcitonin receptor agonists","volume":"20","author":"Cao","year":"2024","journal-title":"Nature Chemical Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0150","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41589-023-01393-4","article-title":"Structural insight into selectivity of amylin and calcitonin receptor agonists","volume":"20","author":"Cao","year":"2024","journal-title":"Nature Chemical Biology"},{"issue":"6587","key":"10.1016\/j.pharmthera.2025.108846_bb0155","doi-asserted-by":"crossref","first-page":"eabm9609","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb0160","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.cmet.2022.10.001","article-title":"The past, present, and future physiology and pharmacology of glucagon","volume":"34","author":"Capozzi","year":"2022","journal-title":"Cell Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0165","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/endrev\/bnac033","article-title":"New insights into the structure and function of class B1 GPCRs","volume":"44","author":"Cary","year":"2023","journal-title":"Endocrine Reviews"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0170","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/en.2016-1755","article-title":"RAMP2 influences glucagon receptor pharmacology via trafficking and signaling","volume":"158","author":"Cegla","year":"2017","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0175","first-page":"551","article-title":"A recombinant calcitonin receptor independently stimulates 3\u2032,5\u2032-cyclic adenosine monophosphate and Ca2+\/inositol phosphate signaling pathways","volume":"6","author":"Chabre","year":"1992","journal-title":"Molecular Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jchf.2013.07.003","article-title":"Urocortin-2 infusion in acute decompensated heart failure: Findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)","volume":"1","author":"Chan","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb0185","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrendo.2015.139","article-title":"PTH receptor-1 signalling-mechanistic insights and therapeutic prospects","volume":"11","author":"Cheloha","year":"2015","journal-title":"Nature Reviews. Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.122.001381","article-title":"HM15912, a novel long-acting glucagon-like Peptide-2 analog, improves intestinal growth and absorption capacity in a male rat model of short bowel syndrome","volume":"384","author":"Choi","year":"2023","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0195","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1074\/jbc.C200629200","article-title":"Novel receptor partners and function of receptor activity-modifying proteins","volume":"278","author":"Christopoulos","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2019.11.036","article-title":"RAMP1 and RAMP3 differentially control amylin\u2019s effects on Food intake, glucose and energy balance in male and female mice","volume":"447","author":"Coester","year":"2020","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-024-00649-0","article-title":"Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins","volume":"10","author":"Cong","year":"2024","journal-title":"Cell Discovery"},{"issue":"40","key":"10.1016\/j.pharmthera.2025.108846_bb0215","article-title":"Constitutive signal bias mediated by the human GHRHR splice variant 1","volume":"118","author":"Cong","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0220","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/mol.58.5.1075","article-title":"Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: Evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity","volume":"58","author":"Cordeaux","year":"2000","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0225","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0026-0495(95)90187-6","article-title":"Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects","volume":"44","author":"Cordido","year":"1995","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0230","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metabolism"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0235","doi-asserted-by":"crossref","first-page":"e3235","DOI":"10.1210\/clinem\/dgab103","article-title":"PREVENT: A randomized, placebo-controlled crossover trial of Avexitide for treatment of Postbariatric hypoglycemia","volume":"106","author":"Craig","year":"2021","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1124\/jpet.112.199752","article-title":"Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways","volume":"345","author":"Cupp","year":"2013","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/acsptsci.8b00056","article-title":"The molecular control of calcitonin receptor signaling","volume":"2","author":"Dal Maso","year":"2019","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcp.2017.12.016","article-title":"Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms","volume":"148","author":"Dal Maso","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114150","article-title":"Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors","volume":"180","author":"Darbalaei","year":"2020","journal-title":"Biochemical Pharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0260","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.bcp.2004.07.013","article-title":"Cell-type specific calcium signaling by corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: Phospholipase C-mediated responses in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells","volume":"68","author":"Dautzenberg","year":"2004","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb0265","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1365-2826.1999.00411.x","article-title":"N-terminal splice variants of the type I PACAP receptor: Isolation, characterization and ligand binding\/selectivity determinants","volume":"11","author":"Dautzenberg","year":"1999","journal-title":"Journal of Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0270","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0275","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41467-021-27760-0","article-title":"Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation","volume":"13","author":"Deganutti","year":"2022","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0303-7207(94)03424-R","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor","volume":"107","author":"Delporte","year":"1995","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/13543784.2021.1857365","article-title":"Adrecizumab: An investigational agent for the biomarker-guided treatment of sepsis","volume":"30","author":"Deniau","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0290","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1016\/S0021-9258(18)42737-8","article-title":"The 38-amino acid form of pituitary adenylate cyclase-activating polypeptide stimulates dual signaling cascades in PC12 cells and promotes neurite outgrowth","volume":"267","author":"Deutsch","year":"1992","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0295","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/bs.mcb.2015.11.010","article-title":"Cellular and subcellular context determine outputs from signaling biosensors","volume":"132","author":"Devost","year":"2016","journal-title":"Methods in Cell Biology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108846_bb0300","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1074\/jbc.M116.763854","article-title":"Conformational profiling of the AT1 angiotensin II receptor reflects biased Agonism, G protein coupling, and cellular context","volume":"292","author":"Devost","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0305","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fendo.2012.00121","article-title":"The neuroendocrine functions of the parathyroid hormone 2 receptor","volume":"3","author":"Dobolyi","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105748","article-title":"The diverse role of corticotropin-releasing factor (CRF) and its CRF1 and CRF2 receptors under pathophysiological conditions: Insights into stress\/anxiety, depression, and brain injury processes","volume":"163","author":"Domin","year":"2024","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113929","article-title":"Rational development of a high-affinity secretin receptor antagonist","volume":"177","author":"Dong","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113929","article-title":"Rational development of a high-affinity secretin receptor antagonist","volume":"177","author":"Dong","year":"2020","journal-title":"Biochemical Pharmacology"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2025.108846_bb0325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10606820213686","article-title":"Molecular pharmacology of the secretin receptor","volume":"8","author":"Dong","year":"2002","journal-title":"Receptors and Channels"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/acsptsci.9b00016","article-title":"The discovery of GLP-2 and development of Teduglutide for short bowel syndrome","volume":"2","author":"Drucker","year":"2019","journal-title":"ACS Pharmacology & Translational Science"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annual Review of Physiology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108846_bb0340","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1021\/acs.jmedchem.9b01810","article-title":"Blocking the CGRP pathway for acute and preventive treatment of migraine: The evolution of success","volume":"63","author":"Dubowchik","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb0345","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.biopsych.2017.06.024","article-title":"Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder","volume":"82","author":"Dunlop","year":"2017","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0350","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0169-328X(95)00253-O","article-title":"Structure of a parathyroid hormone\/parathyroid hormone-related peptide receptor of the human cerebellum and functional expression in human neuroblastoma SK-N-MC cells","volume":"36","author":"Eggenberger","year":"1996","journal-title":"Brain Research. Molecular Brain Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0355","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: A systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Injury"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0360","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/acsptsci.0c00022","article-title":"The influence of peptide context on signaling and trafficking of glucagon-like Peptide-1 receptor biased agonists","volume":"3","author":"Fang","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0365","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/edrv-16-3-390","article-title":"Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide","volume":"16","author":"Fehmann","year":"1995","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0370","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2012.01979.x","article-title":"Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats","volume":"167","author":"Feigh","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0375","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ckj\/sfv011","article-title":"Calcitonin, the forgotten hormone: Does it deserve to be forgotten?","volume":"8","author":"Felsenfeld","year":"2015","journal-title":"Clinical Kidney Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-7843.2007.00008.x","article-title":"Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue","volume":"100","author":"Ferdinandi","year":"2007","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0385","doi-asserted-by":"crossref","first-page":"1ps1","DOI":"10.1126\/scitranslmed.3000268","article-title":"Beta-arrestin-biased parathyroid hormone ligands: A new approach to the development of agents that stimulate bone formation","volume":"1","author":"Ferrari","year":"2009","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0390","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1210\/en.2004-1282","article-title":"Bone response to intermittent parathyroid hormone is altered in mice null for beta-Arrestin2","volume":"146","author":"Ferrari","year":"2005","journal-title":"Endocrinology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108846_bb0395","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/bph.13866","article-title":"Galpha(s) signalling of the CB(1) receptor and the influence of receptor number","volume":"174","author":"Finlay","year":"2017","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0400","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bcp.2018.09.003","article-title":"Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists","volume":"156","author":"Fletcher","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0405","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison to six selective and non-selective agonists","author":"Fletcher","year":"2021","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0410","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0415","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"10403","key":"10.1016\/j.pharmthera.2025.108846_bb0420","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0425","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1053\/j.gastro.2010.01.049","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion","volume":"138","author":"Fujita","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1476-5381.2011.01571.x","article-title":"Consequences of splice variation on secretin family G protein-coupled receptor function","volume":"166","author":"Furness","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0435","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2016.09.021","article-title":"Ligand-dependent modulation of G protein conformation alters drug efficacy","volume":"167","author":"Furness","year":"2016","journal-title":"Cell"},{"issue":"S6","key":"10.1016\/j.pharmthera.2025.108846_bb0440","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bcpt.13289","article-title":"Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system","volume":"126","author":"Gabe","year":"2020","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108846_bb0445","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/bph.16040","article-title":"Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice","volume":"180","author":"Gabe","year":"2023","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0450","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism [Mini review]","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Frontiers in Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0455","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/mol.109.055756","article-title":"Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor","volume":"76","author":"Gao","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0460","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.celrep.2020.01.029","article-title":"Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (Erenumab)","volume":"30","author":"Garces","year":"2020","journal-title":"Cell Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0465","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide","volume":"374","author":"Garcia-Martinez","year":"2020","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0470","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bph.16218","article-title":"Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors","volume":"181","author":"Garelja","year":"2024","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0475","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1021\/acsptsci.9b00083","article-title":"Molecular mechanisms of class B GPCR activation: Insights from Adrenomedullin receptors","volume":"3","author":"Garelja","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0480","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bph.15628","article-title":"Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors","volume":"179","author":"Garelja","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108846_bb0485","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1074\/jbc.M513380200","article-title":"Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1\/2 activation","volume":"281","author":"Gesty-Palmer","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0490","doi-asserted-by":"crossref","first-page":"1ra1","DOI":"10.1126\/scitranslmed.3000071","article-title":"A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0495","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"year":"2020","series-title":"Sermorelin acetate: Summary report","author":"Gianturco","key":"10.1016\/j.pharmthera.2025.108846_bb0500"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0505","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acsptsci.9b00089","article-title":"Distinct patterns of internalization of different calcitonin gene-related peptide receptors","volume":"3","author":"Gingell","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"26","key":"10.1016\/j.pharmthera.2025.108846_bb0510","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"Goke","year":"1993","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0515","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","article-title":"Physiology of parathyroid hormone","volume":"47","author":"Goltzman","year":"2018","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"32","key":"10.1016\/j.pharmthera.2025.108846_bb0520","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.1016\/S0021-9258(18)47756-3","article-title":"Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes","volume":"262","author":"Grady","year":"1987","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0525","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnins.2017.00017","article-title":"A practical guide to approaching biased Agonism at G protein coupled receptors","volume":"11","author":"Gundry","year":"2017","journal-title":"Frontiers in Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0530","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-020-01097-3","article-title":"Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies","volume":"21","author":"Haanes","year":"2020","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0540","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1038\/s41467-022-33307-8","article-title":"beta-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells","volume":"13","author":"Haider","year":"2022","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0545","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2015.122","article-title":"Regulation of glucose metabolism from a liver-centric perspective","volume":"48","author":"Han","year":"2016","journal-title":"Experimental & Molecular Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0550","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/0196-9781(95)00078-X","article-title":"Glucagon receptor mRNA distribution in rat tissues","volume":"16","author":"Hansen","year":"1995","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0555","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.119.262238","article-title":"Pharmacological characterization of Apraglutide, a novel long-acting Peptidic glucagon-like Peptide-2 agonist, for the treatment of short bowel syndrome","volume":"373","author":"Hargrove","year":"2020","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"D1","key":"10.1016\/j.pharmthera.2025.108846_bib1596","doi-asserted-by":"crossref","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024","volume":"52","author":"Harding","year":"2024","journal-title":"Nucleic Acids Research"},{"issue":"42","key":"10.1016\/j.pharmthera.2025.108846_bb0560","doi-asserted-by":"crossref","first-page":"30363","DOI":"10.1074\/jbc.M702325200","article-title":"Transmembrane segment IV contributes a functionally important interface for oligomerization of the class II G protein-coupled secretin receptor","volume":"282","author":"Harikumar","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0565","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1038\/s41467-024-48853-6","article-title":"Impact of secretin receptor homo-dimerization on natural ligand binding","volume":"15","author":"Harikumar","year":"2024","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0570","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2012.01871.x","article-title":"Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1","volume":"166","author":"Harmar","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0575","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of Abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0580","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/pr.55.1.3","article-title":"International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands","volume":"55","author":"Hauger","year":"2003","journal-title":"Pharmacological Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb0585","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11892-019-1216-4","article-title":"Novel preparations of glucagon for the prevention and treatment of hypoglycemia","volume":"19","author":"Hawkes","year":"2019","journal-title":"Current Diabetes Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0590","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: Pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacological Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25","volume":"175","author":"Hay","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108846_bb0600","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pharmthera.2005.06.015","article-title":"GPCR modulation by RAMPs","volume":"109","author":"Hay","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0605","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.physbeh.2010.02.029","article-title":"Role of the glucagon-like-peptide-1 receptor in the control of energy balance","volume":"100","author":"Hayes","year":"2010","journal-title":"Physiology & Behavior"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0610","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb0615","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrn.2016.94","article-title":"Region-specific roles of the corticotropin-releasing factor-urocortin system in stress","volume":"17","author":"Henckens","year":"2016","journal-title":"Nature Reviews. Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0620","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bjp.0702359","article-title":"Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists","volume":"126","author":"Hermans","year":"1999","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0625","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1677\/joe.0.1660213","article-title":"Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors","volume":"166","author":"Hilton","year":"2000","journal-title":"The Journal of Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0630","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/dom.15288","article-title":"Abolishing beta-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists","volume":"26","author":"Hinds","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0635","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s10194-018-0855-1","article-title":"Discovery of PACAP and its receptors in the brain","volume":"19","author":"Hirabayashi","year":"2018","journal-title":"The Journal of Headache and Pain"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0640","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tips.2013.11.001","article-title":"Insights into the structure of class B GPCRs","volume":"35","author":"Hollenstein","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0645","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: The role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0650","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4614-2364-5_8","article-title":"Regulation of RAMP expression in diseases","volume":"744","author":"Jacob","year":"2012","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0655","first-page":"12","article-title":"The road towards triple agonists: Glucagon-like peptide 1, glucose-dependent Insulinotropic polypeptide and glucagon receptor - an update","volume":"39","author":"Jakubowska","year":"2024","journal-title":"enm"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.832589","article-title":"Lipidated calcitonin gene-related peptide (CGRP) peptide antagonists retain CGRP receptor activity and attenuate CGRP action in vivo [original research]","volume":"13","author":"Jamaluddin","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"5101","key":"10.1016\/j.pharmthera.2025.108846_bb0665","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.8384375","article-title":"Expression cloning and signaling properties of the rat glucagon receptor","volume":"259","author":"Jelinek","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.928016","article-title":"Role of glucagon and its receptor in the pathogenesis of diabetes [Mini review]","volume":"13","author":"Jia","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0675","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016334","article-title":"Genetic and biased agonist-mediated reductions in beta-arrestin recruitment prolong cAMP signaling at glucagon family receptors","volume":"296","author":"Jones","year":"2021","journal-title":"The Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0680","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1124\/jpet.107.120006","article-title":"Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s)","volume":"322","author":"Jorgensen","year":"2007","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0685","series-title":"Principles of bone biology (pp. 1117-XLI)","article-title":"Jansen\u2019s metaphyseal chondrodysplasia and Blomstrand\u2019s lethal chondrodysplasia: Two genetic disorders caused by PTH\/PTHrP receptor mutations","author":"J\u00fcppner","year":"2002"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0690","doi-asserted-by":"crossref","first-page":"rkx008","DOI":"10.1093\/rap\/rkx008","article-title":"Rheumatoid arthritis: The journey in pursuit of a cure","volume":"1","author":"Karponis","year":"2017","journal-title":"Rheumatology Advances in Practice"},{"issue":"49","key":"10.1016\/j.pharmthera.2025.108846_bb0695","doi-asserted-by":"crossref","first-page":"16630","DOI":"10.1074\/jbc.RA120.014532","article-title":"Agonist-activated glucagon receptors are deubiquitinated at early endosomes by two distinct deubiquitinases to facilitate Rab4a-dependent recycling","volume":"295","author":"Kaur","year":"2020","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0700","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.peptides.2018.07.010","article-title":"Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons","volume":"107","author":"Kawatani","year":"2018","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0705","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: Detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0710","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0715","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/molpharm.123.000865","article-title":"Development of a novel assay for direct assessment of selective amylin receptor activation reveals novel differences in behavior of selective and nonselective peptide agonists","volume":"105","author":"Keov","year":"2024","journal-title":"Molecular Pharmacology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108846_bb0720","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.1073\/pnas.1533185100","article-title":"Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor","volume":"100","author":"Kiaris","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0725","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10253890.2017.1336535","article-title":"Pituitary adenylate cyclase activating polypeptide (PACAP), stress, and sex hormones","volume":"20","author":"King","year":"2017","journal-title":"Stress"},{"issue":"D1","key":"10.1016\/j.pharmthera.2025.108846_bib1597","doi-asserted-by":"crossref","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0730","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00535-020-01741-4","article-title":"Adrenomedullin for steroid-resistant ulcerative colitis: A randomized, double-blind, placebo-controlled phase-2a clinical trial","volume":"56","author":"Kita","year":"2021","journal-title":"Journal of Gastroenterology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb0735","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/jgh.15945","article-title":"Adrenomedullin for biologic-resistant Crohn\u2019s disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial","volume":"37","author":"Kita","year":"2022","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108846_bb0740","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nature Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0745","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1038\/ncomms10842","article-title":"The role of kinetic context in apparent biased agonism at GPCRs","volume":"7","author":"Klein Herenbrink","year":"2016","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0750","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030536","article-title":"Secretin receptor as a target in gastrointestinal Cancer: Expression analysis and ligand development","volume":"10","author":"Klussmeier","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0755","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: Pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108846_bb0760","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1111\/bph.15811","article-title":"Community guidelines for GPCR ligand bias: IUPHAR review 32","volume":"179","author":"Kolb","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0765","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1073\/pnas.87.6.2299","article-title":"Secretin: Structure of the precursor and tissue distribution of the mRNA","volume":"87","author":"Kopin","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0770","first-page":"1077","article-title":"Molecular identification and analysis of a novel human Corticotropin-releasing factor (CRF) receptor: The CRF2\u03b3 receptor","volume":"12","author":"Kostich","year":"1998","journal-title":"Molecular Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0775","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.292.2.210","article-title":"Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: A randomized controlled trial","volume":"292","author":"Koutkia","year":"2004","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0780","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/cts.13114","article-title":"Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta-analysis","volume":"14","author":"Kovacs","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0785","doi-asserted-by":"crossref","first-page":"C1230","DOI":"10.1152\/ajpcell.00240.2008","article-title":"Glucagon receptor recycling: Role of carboxyl terminus, beta-arrestins, and cytoskeleton","volume":"295","author":"Krilov","year":"2008","journal-title":"American Journal of Physiology. Cell Physiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108846_bb0790","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.cell.2023.02.028","article-title":"Negative allosteric modulation of the glucagon receptor by RAMP2","volume":"186","author":"Krishna Kumar","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-023-01569-2","article-title":"Shared and independent roles of CGRP and PACAP in migraine pathophysiology","volume":"24","author":"Kuburas","year":"2023","journal-title":"The Journal of Headache and Pain"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0800","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/npp.2014.306","article-title":"The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: A randomized controlled experimental medicine study","volume":"40","author":"Kwako","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? - comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"10317","key":"10.1016\/j.pharmthera.2025.108846_bb0810","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.737686","article-title":"Pleiotropic effects of secretin: A potential drug candidate in the treatment of obesity? [review]","volume":"12","author":"Laurila","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0820","article-title":"Calcitonin and amylin receptor peptide interaction mechanisms: Insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins","author":"Lee","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108846_bb0825","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/acschemneuro.1c00135","article-title":"To probe the binding interactions between two FDA approved migraine drugs (Ubrogepant and Rimegepant) and calcitonin-gene related peptide receptor (CGRPR) using molecular dynamics simulations","volume":"12","author":"Leung","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"issue":"33","key":"10.1016\/j.pharmthera.2025.108846_bb0830","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303696120","article-title":"Structural analysis of the dual agonism at GLP-1R and GCGR","volume":"120","author":"Li","year":"2023","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb0835","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.molcel.2020.01.012","article-title":"Toward a structural understanding of class B GPCR peptide binding and activation","volume":"77","author":"Liang","year":"2020","journal-title":"Molecular Cell"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108846_bb0840","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1042\/BCJ20200235","article-title":"Characterization of a naturally occurring mutation V368M in the human glucagon receptor and its association with metabolic disorders","volume":"477","author":"Lin","year":"2020","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0845","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0006-291X(84)90475-3","article-title":"Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1","volume":"122","author":"Ling","year":"1984","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0850","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0855","doi-asserted-by":"crossref","first-page":"eaaw2778","DOI":"10.1126\/sciadv.aaw2778","article-title":"Multiplexed analysis of the secretin-like GPCR-RAMP interactome","volume":"5","author":"Lorenzen","year":"2019","journal-title":"Science Advances"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb0860","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00018-011-0905-1","article-title":"Control of energy homeostasis by amylin","volume":"69","author":"Lutz","year":"2012","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0865","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiology & Behavior"},{"issue":"suppl_1","key":"10.1016\/j.pharmthera.2025.108846_bb0870","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1530\/eje.1.02247","article-title":"Corticotropin-releasing hormone physiology","volume":"155","author":"Majzoub","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb0875","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad028","article-title":"Enhanced endosomal signaling and desensitization of GLP-1R vs GIPR in pancreatic Beta cells","volume":"164","author":"Manchanda","year":"2023","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb0880","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1172\/JCI26239","article-title":"Osteoblast-derived PTHrP is a physiological regulator of bone formation","volume":"115","author":"Martin","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"issue":"7835","key":"10.1016\/j.pharmthera.2025.108846_bb0885","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41586-020-2888-2","article-title":"Combinatorial expression of GPCR isoforms affects signalling and drug responses","volume":"587","author":"Marti-Solano","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114656","article-title":"Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1","volume":"190","author":"Marzook","year":"2021","journal-title":"Biochemical Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0895","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/en.2003-0301","article-title":"Corticotropin-releasing hormone-mediated pathway of leptin to regulate feeding, adiposity, and uncoupling protein expression in mice","volume":"144","author":"Masaki","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0900","first-page":"35","article-title":"Growth hormone-releasing hormone: Synthesis and signaling","volume":"50","author":"Mayo","year":"1995","journal-title":"Recent Progress in Hormone Research"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101296","article-title":"Receptor activity-modifying protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling","volume":"53","author":"McGlone","year":"2021","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0910","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1476-5381.2011.01774.x","article-title":"G-protein betagamma subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide","volume":"166","author":"Meens","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic beta-cells: Mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb0920","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0026-0495(99)90115-4","article-title":"Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus","volume":"48","author":"Micic","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0925","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108846_bb0930","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb0935","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00198-008-0732-x","article-title":"Measuring serum calcium before and after teriparatide treatment","volume":"19","author":"Minisola","year":"2008","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0940","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/jpet.118.253443","article-title":"Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide","volume":"369","author":"Moldovan Loomis","year":"2019","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb0945","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MED.0b013e328342568a","article-title":"VIP and PACAP: Recent insights into their functions\/roles in physiology and disease from molecular and genetic studies","volume":"18","author":"Moody","year":"2011","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb0950","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1210\/en.2007-1735","article-title":"Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors","volume":"149","author":"Morfis","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0955","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Molecular Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb0960","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiological Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb0965","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1210\/jc.2016-2054","article-title":"Jansen metaphyseal chondrodysplasia due to heterozygous H223R-PTH1R mutations with or without overt hypercalcemia","volume":"101","author":"Nampoothiri","year":"2016","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0970","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","volume":"23 Suppl 3(S3)","author":"Nauck","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb0975","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/13543784.2012.681044","article-title":"CGRP receptor antagonists: An expanding drug class for acute migraine?","volume":"21","author":"Negro","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101181","article-title":"Spatiotemporal GLP-1 and GIP receptor signaling and trafficking\/recycling dynamics induced by selected receptor mono- and dual-agonists","volume":"49","author":"Novikoff","year":"2021","journal-title":"Molecular Metabolism"},{"issue":"43","key":"10.1016\/j.pharmthera.2025.108846_bb0985","doi-asserted-by":"crossref","first-page":"16525","DOI":"10.1073\/pnas.0808750105","article-title":"Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation","volume":"105","author":"Okazaki","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb0990","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1210\/jc.2018-00655","article-title":"The intestinotrophic effects of glucagon-like Peptide-2 in relation to intestinal neoplasia","volume":"103","author":"Orhan","year":"2018","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108846_bb0995","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","article-title":"Antagonism of CGRP signaling by Rimegepant at two receptors","volume":"11","author":"Pan","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb1000","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0333102420937655","article-title":"Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers","volume":"40","author":"Pellesi","year":"2020","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1005","doi-asserted-by":"crossref","first-page":"C783","DOI":"10.1152\/ajpcell.00452.2021","article-title":"Endosomal parathyroid hormone receptor signaling","volume":"323","author":"Pena","year":"2022","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2023.112107","article-title":"Endosomal signaling via cAMP in parathyroid hormone (PTH) type 1 receptor biology","volume":"581","author":"Pena","year":"2024","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1015","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2021.698240","article-title":"Acute Corticotropin-releasing factor receptor type 2 Agonism results in sustained symptom improvement in Myalgic encephalomyelitis\/chronic fatigue syndrome [original research]","volume":"15","author":"Pereira","year":"2021","journal-title":"Frontiers in Systems Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb1020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/db22-1039","article-title":"Optimization of a glucagon-like peptide 1 receptor antagonist antibody for treatment of Hyperinsulinism","volume":"72","author":"Peterson","year":"2023","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb1025","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","article-title":"Glucagon receptor antagonist volagidemab in type 1 diabetes: A 12-week, randomized, double-blind, phase 2 trial","volume":"28","author":"Pettus","year":"2022","journal-title":"Nature Medicine"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108846_bb1030","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1111\/bph.15134","article-title":"Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide","volume":"177","author":"Pickford","year":"2020","journal-title":"British Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb1035","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1359\/jbmr.081237","article-title":"Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice","volume":"24","author":"Pierroz","year":"2009","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1040","doi-asserted-by":"crossref","first-page":"R340","DOI":"10.1152\/ajpregu.00380.2011","article-title":"Involvement of the extracellular signal-regulated kinase 1\/2 signaling pathway in amylin\u2019s eating inhibitory effect","volume":"302","author":"Potes","year":"2012","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00063030-199912020-00007","article-title":"Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency","volume":"12","author":"Prakash","year":"1999","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1476-5381.2012.02197.x","article-title":"Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Delta(1-47)hCT((a)) function","volume":"168","author":"Qi","year":"2013","journal-title":"British Journal of Pharmacology"},{"issue":"6484","key":"10.1016\/j.pharmthera.2025.108846_bb1055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.aaz5346","article-title":"Structural basis of G<sub>s<\/sub> and G<sub>i<\/sub> recognition by the human glucagon receptor","volume":"367","author":"Qiao","year":"2020","journal-title":"Science"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108846_bb1060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anireprosci.2005.05.009","article-title":"GnRH in non-hypothalamic reproductive tissues","volume":"88","author":"Ramakrishnappa","year":"2005","journal-title":"Animal Reproduction Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1065","doi-asserted-by":"crossref","first-page":"G263","DOI":"10.1152\/ajpgi.00275.2018","article-title":"Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na(+),K(+)-ATPase in pancreatic acinar cells","volume":"316","author":"Ramos-Alvarez","year":"2019","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1070","doi-asserted-by":"crossref","first-page":"1463313","DOI":"10.3389\/fphar.2024.1463313","article-title":"Tirzepatide, GIP(1-42) and GIP(1\u221230) display unique signaling profiles at two common GIP receptor variants, E354 and Q354 [original research]","volume":"15","author":"Rees","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bph.15605","article-title":"Beyond CGRP: The calcitonin peptide family as targets for migraine and pain","volume":"179","author":"Rees","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb1080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.tips.2023.07.003","article-title":"Calcitonin\/PAC(1) receptor splice variants: A blind spot in migraine research","volume":"44","author":"Rees","year":"2023","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1085","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.860037","article-title":"CGRP and the calcitonin receptor are co-expressed in mouse, rat and human trigeminal ganglia neurons [original research]","volume":"13","author":"Rees","year":"2022","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s10194-024-01744-z","article-title":"Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1\/2 dorsal root ganglia","volume":"25","author":"Rees","year":"2024","journal-title":"The Journal of Headache and Pain"},{"issue":"10329","key":"10.1016\/j.pharmthera.2025.108846_bb1095","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1100","doi-asserted-by":"crossref","first-page":"R1833","DOI":"10.1152\/ajpregu.2001.281.6.R1833","article-title":"Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP","volume":"281","author":"Riediger","year":"2001","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1105","article-title":"Reporting in vitro experiments responsibly \u2013 The RIVER recommendations. [preprint]","author":"River","year":"2023","journal-title":"MetaArXiv"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1432-1033.1992.tb17043.x","article-title":"Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist","volume":"207","author":"Robberecht","year":"1992","journal-title":"European Journal of Biochemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb1115","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15263","article-title":"Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty","volume":"10","author":"Rodgers","year":"2022","journal-title":"Physiological Reports"},{"issue":"7894","key":"10.1016\/j.pharmthera.2025.108846_bb1120","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(74)90072-5","article-title":"Paget\u2019s bone disease: Response to human calcitonin in patients resistant to salmon calcitonin","volume":"2","author":"Rojanasathit","year":"1974","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb1125","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.bjp.0705120","article-title":"Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity","volume":"138","author":"Runge","year":"2003","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: Physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiological Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1135","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond","volume":"103","author":"Russo","year":"2023","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1140","series-title":"Google Patents","article-title":"Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers","author":"Russo","year":"2017"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1145","first-page":"203","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2009","journal-title":"Drug Design, Development and Therapy"},{"issue":"3951","key":"10.1016\/j.pharmthera.2025.108846_bb1150","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.169.3951.1217","article-title":"Polypeptide with broad biological activity: Isolation from small intestine","volume":"169","author":"Said","year":"1970","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb1155","article-title":"Shifting the scales: Tirzepatide\u2019s breakthrough in obesity management","volume":"16","author":"Sallam","year":"2024","journal-title":"Cureus"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108846_bb1160","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: first global approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108846_bb1165","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10441","article-title":"Comparable initial engagement of intracellular signaling pathways by parathyroid hormone receptor ligands Teriparatide, Abaloparatide, and long-acting PTH","volume":"5","author":"Sato","year":"2021","journal-title":"JBMR Plus"},{"issue":"7\u20138","key":"10.1016\/j.pharmthera.2025.108846_bb1170","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/psc.2953","article-title":"Adrenomedullin - new perspectives of a potent peptide hormone","volume":"23","author":"Schonauer","year":"2017","journal-title":"Journal of Peptide Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108846_bb1175","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1038\/npp.2016.61","article-title":"The CRF1 antagonist Verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, But not of Anti-Craving Effects","volume":"41","author":"Schwandt","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2025.108846_bb1180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.peptides.2017.11.013","article-title":"Problem or solution: The strange story of glucagon","volume":"100","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2019.05.006","article-title":"Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR\/transducer selectivity and therapeutic potential","volume":"200","author":"Seyedabadi","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.apsb.2021.07.028","article-title":"Modulating effects of RAMPs on signaling profiles of the glucagon receptor family","volume":"12","author":"Shao","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.115.227793","article-title":"Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor","volume":"356","author":"Shi","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108846_bb1210","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in Thyroparathyroidectomized (TPTX) rats and Normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2025.108846_bb1215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.regpep.2006.02.011","article-title":"Signaling mechanisms of secretin receptor","volume":"137","author":"Siu","year":"2006","journal-title":"Regulatory Peptides"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1220","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/pr.110.002667","article-title":"Allostery at G protein-coupled receptor homo- and heteromers: Uncharted pharmacological landscapes","volume":"62","author":"Smith","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108846_bb1225","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1230","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00006676-200310000-00006","article-title":"Comparison of biologic porcine secretin, synthetic porcine secretin, and synthetic human secretin in pancreatic function testing","volume":"27","author":"Somogyi","year":"2003","journal-title":"Pancreas"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108846_bb1235","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1073\/pnas.0710402105","article-title":"Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells","volume":"105","author":"Sonoda","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6442","key":"10.1016\/j.pharmthera.2025.108846_bb1240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/365170a0","article-title":"Differential signal transduction by five splice variants of the PACAP receptor","volume":"365","author":"Spengler","year":"1993","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1245","first-page":"600","article-title":"Calcitonin: A useful old friend","volume":"20","author":"Srinivasan","year":"2020","journal-title":"Journal of Musculoskeletal & Neuronal Interactions"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fendo.2012.00103","article-title":"Hormone-stimulated modulation of endocytic trafficking in osteoclasts","volume":"3","author":"Stenbeck","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1260","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.gene.2015.05.065","article-title":"HEK293 in cell biology and cancer research: Phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution","volume":"569","author":"Stepanenko","year":"2015","journal-title":"Gene"},{"issue":"Supplement_2","key":"10.1016\/j.pharmthera.2025.108846_bb1265","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.964","article-title":"Long-acting CRF2 peptide agonist improves cardiac function in a rat heart failure model","volume":"44","author":"Stephan","year":"2023","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF03345791","article-title":"Secretin: Should we revisit its metabolic outcomes?","volume":"33","author":"St-Pierre","year":"2010","journal-title":"Journal of Endocrinological Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/bbrc.1996.1035","article-title":"Glucose-dependent insulinotropic polypeptide stimulates insulin secretion via increased cyclic AMP and [Ca2+]1 and a wortmannin-sensitive signalling pathway","volume":"224","author":"Straub","year":"1996","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2197-425X-1-3","article-title":"Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model","volume":"1","author":"Struck","year":"2013","journal-title":"Intensive Care Medicine Experimental"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1285","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1210\/endo.131.3.1324163","article-title":"Differential effects of the 3\u2032,5\u2032-cyclic adenosine monophosphate and protein kinase C pathways on the response of isolated rat osteoclasts to calcitonin","volume":"131","author":"Su","year":"1992","journal-title":"Endocrinology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108846_bb1290","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb1295","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1210\/endo.137.11.8895334","article-title":"Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts","volume":"137","author":"Suzuki","year":"1996","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1300","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.9b00835","article-title":"Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors","volume":"63","author":"Suzuki","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1305","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-7207(94)90162-7","article-title":"Relative quantitative analysis of glucagon receptor mRNA in rat tissues","volume":"105","author":"Svoboda","year":"1994","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb1310","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/dom.14048","article-title":"Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia","volume":"22","author":"Tan","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108846_bb1315","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/bph.16376","article-title":"Pharmacology of PACAP and VIP receptors in the spinal cord highlights the importance of the PAC(1) receptor","volume":"181","author":"Tasma","year":"2024","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1320","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bph.15700","article-title":"Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery","volume":"179","author":"Tasma","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1325","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bph.15700","article-title":"Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery [doi:10.1111\/bph.15700]","volume":"179","author":"Tasma","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1330","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.595","article-title":"Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors","volume":"8","author":"Tasma","year":"2020","journal-title":"Pharmacology Research & Perspectives"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb1335","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2337\/diab.42.11.1678","article-title":"Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor","volume":"42","author":"Thorens","year":"1993","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3565(24)39040-8","article-title":"Amylin receptor phenotypes derived from human calcitonin receptor\/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment","volume":"294","author":"Tilakaratne","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb1345","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1073\/pnas.84.10.3146","article-title":"Secretin stimulates cyclic AMP and inositol trisphosphate production in rat pancreatic acinar tissue by two fully independent mechanisms","volume":"84","author":"Trimble","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1350","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/en.2009-0546","article-title":"Mechanisms of amylin\/leptin synergy in rodent models","volume":"151","author":"Turek","year":"2010","journal-title":"Endocrinology"},{"author":"U.S. Food and Drug Administration, C. f. D. E. a. R","key":"10.1016\/j.pharmthera.2025.108846_bb1355"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1360","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1124\/mol.105.021915","article-title":"Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors","volume":"69","author":"Udawela","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"D1","key":"10.1016\/j.pharmthera.2025.108846_bb1365","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: The universal protein knowledgebase in 2021","volume":"49","author":"UniProt","year":"2021","journal-title":"Nucleic Acids Research"},{"issue":"50","key":"10.1016\/j.pharmthera.2025.108846_bb1370","first-page":"E8178","article-title":"Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties","volume":"113","author":"Urs","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7436","key":"10.1016\/j.pharmthera.2025.108846_bb1375","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature11896","article-title":"Molecular signatures of G-protein-coupled receptors","volume":"494","author":"Venkatakrishnan","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1380","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0026-895X(25)10175-2","article-title":"Properties and regulation of the coupling to adenylate cyclase of the secretin receptor stably transfected in CHO cells","volume":"45","author":"Vilardaga","year":"1994","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-010-0465-9","article-title":"Molecular basis of parathyroid hormone receptor signaling and trafficking: A family B GPCR paradigm","volume":"68","author":"Vilardaga","year":"2011","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108846_bb1390","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/bph.16372","article-title":"Intracellular pathways of calcitonin gene-related peptide-induced relaxation of human coronary arteries: A key role for Gbetagamma subunit instead of cAMP","volume":"181","author":"de Vries","year":"2024","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1395","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endo.137.1.8536630","article-title":"Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase alpha-mediated mechanism","volume":"137","author":"Wada","year":"1996","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1400","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/acn3.197","article-title":"A second trigeminal CGRP receptor: Function and expression of the AMY1 receptor","volume":"2","author":"Walker","year":"2015","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1405","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0333102417691762","article-title":"CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured","volume":"38","author":"Walker","year":"2018","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1410","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/bph.12541","article-title":"PACAP receptor pharmacology and agonist bias: Analysis in primary neurons and glia from the trigeminal ganglia and transfected cells","volume":"171","author":"Walker","year":"2014","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1415","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/ciia.2006.1.4.307","article-title":"Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?","volume":"1","author":"Walker","year":"2006","journal-title":"Clinical Interventions in Aging"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1420","doi-asserted-by":"crossref","first-page":"32246","DOI":"10.1038\/srep32246","article-title":"Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis","volume":"6","author":"Wang","year":"2016","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108846_bb1425","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.1424934112","article-title":"Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway","volume":"112","author":"Wang","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1430","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41401-021-00758-6","article-title":"Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"issue":"38","key":"10.1016\/j.pharmthera.2025.108846_bb1435","doi-asserted-by":"crossref","first-page":"23009","DOI":"10.1074\/jbc.M114.624601","article-title":"Modulation of glucagon receptor pharmacology by receptor activity-modifying Protein-2 (RAMP2)","volume":"290","author":"Weston","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108846_bb1440","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1111\/bph.12716","article-title":"Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast","volume":"171","author":"Weston","year":"2014","journal-title":"British Journal of Pharmacology"},{"year":"2020","series-title":"Molecular and cellular mechanisms regulating PTH receptor signaling and","author":"White","key":"10.1016\/j.pharmthera.2025.108846_bb1445"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108846_bb1450","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"Volume 46","key":"10.1016\/j.pharmthera.2025.108846_bb1455","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.ph.46.030184.002045","article-title":"Regulatory mechanisms in pancreas and salivary acini","volume":"46","author":"Williams","year":"1984","journal-title":"Annual Review of Physiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb1460","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"841","key":"10.1016\/j.pharmthera.2025.108846_bb1465","doi-asserted-by":"crossref","first-page":"eadi4747","DOI":"10.1126\/scisignal.adi4747","article-title":"Conformation- and activation-based BRET sensors differentially report on GPCR-G protein coupling","volume":"17","author":"Wright","year":"2024","journal-title":"Science Signaling"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1470","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1038\/s41467-023-41893-4","article-title":"GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics","volume":"14","author":"Wright","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1475","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41467-020-14934-5","article-title":"Full-length human GLP-1 receptor structure without orthosteric ligands","volume":"11","author":"Wu","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174203","article-title":"Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects","volume":"907","author":"Wu","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1485","doi-asserted-by":"crossref","first-page":"3236828","DOI":"10.1155\/2020\/3236828","article-title":"Calcitonin and bone physiology: In vitro, in vivo, and clinical investigations","volume":"2020","author":"Xie","year":"2020","journal-title":"International Journal of Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1490","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/10799890903295150","article-title":"Glucagon receptor mediates calcium signaling by coupling to G alpha q\/11 and G alpha i\/o in HEK293 cells","volume":"29","author":"Xu","year":"2009","journal-title":"Journal of Receptor and Signal Transduction Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1495","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/jpet.108.147009","article-title":"Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys","volume":"329","author":"Yan","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1500","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: Structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108846_bb1505","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.apsb.2024.06.023","article-title":"Genome-wide pan-GPCR cell libraries accelerate drug discovery","volume":"14","author":"Yang","year":"2024","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1510","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12020-008-9092-8","article-title":"Calcitonin induces expression of the inducible cAMP early repressor in osteoclasts","volume":"33","author":"Yang","year":"2008","journal-title":"Endocrine"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1515","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: Systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"46","key":"10.1016\/j.pharmthera.2025.108846_bb1520","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.1073\/pnas.1706656114","article-title":"Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission","volume":"114","author":"Yarwood","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108846_bb1525","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bjan.2019.08.004","article-title":"Calcitonin as an analgesic agent: Review of mechanisms of action and clinical applications","volume":"69","author":"Yazdani","year":"2019","journal-title":"Braz J Anesthesiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108846_bb1530","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Development Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb1535","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/CCM.0000000000005660","article-title":"The use of IV vasoactive intestinal peptide (Aviptadil) in patients with critical COVID-19 respiratory failure: Results of a 60-day randomized controlled trial","volume":"50","author":"Youssef","year":"2022","journal-title":"Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114001","article-title":"Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors","volume":"177","author":"Yuliantie","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1545","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114715","article-title":"Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor","volume":"192","author":"Yuliantie","year":"2021","journal-title":"Biochemical Pharmacology"},{"issue":"28","key":"10.1016\/j.pharmthera.2025.108846_bb1550","doi-asserted-by":"crossref","first-page":"24896","DOI":"10.1074\/jbc.M201358200","article-title":"Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase","volume":"277","author":"Yusta","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"issue":"43","key":"10.1016\/j.pharmthera.2025.108846_bb1555","doi-asserted-by":"crossref","first-page":"30459","DOI":"10.1074\/jbc.274.43.30459","article-title":"Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor","volume":"274","author":"Yusta","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108846_bb1560","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1677\/joe.0.1260473","article-title":"Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways","volume":"126","author":"Zaidi","year":"1990","journal-title":"The Journal of Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108846_bb1565","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113326","article-title":"GLP-1 and GIP receptors signal through distinct beta-arrestin 2-dependent pathways to regulate pancreatic beta cell function","volume":"42","author":"Zaimia","year":"2023","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2025.108846_bb1570","series-title":"Google Patents","article-title":"Antagonist antibodies directed against calcitonin gene-related peptide and methods using same","author":"Zeller","year":"2011"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1575","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-022-34009-x","article-title":"Molecular insights into the distinct signaling duration for the peptide-induced PTH1R activation","volume":"13","author":"Zhai","year":"2022","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108846_bb1580","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3233\/JPD-202318","article-title":"Neuroprotective effects of a GLP-2 analogue in the MPTP Parkinson\u2019s disease mouse model","volume":"11","author":"Zhang","year":"2021","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"7979","key":"10.1016\/j.pharmthera.2025.108846_bb1585","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-06467-w","article-title":"Conserved class B GPCR activation by a biased intracellular agonist","volume":"621","author":"Zhao","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108846_bb1590","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41467-020-18945-0","article-title":"Structural basis for activation of the growth hormone-releasing hormone receptor","volume":"11","author":"Zhou","year":"2020","journal-title":"Nature Communications"},{"issue":"9\u201310","key":"10.1016\/j.pharmthera.2025.108846_bb1595","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2010.02.011","article-title":"Progress in corticotropin-releasing factor-1 antagonist development","volume":"15","author":"Zorrilla","year":"2010","journal-title":"Drug Discovery Today"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:45:53Z","timestamp":1753796753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":321,"alternative-id":["S0163725825000580"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108846","relation":{},"ISSN":["0163-7258"],"issn-type":[{"type":"print","value":"0163-7258"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108846"}}